BriaCell Therapeutics Corp. — Form 10-K
Filed October 28, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 18/100
What the filing says
As of July 31, 2026, BriaCell had 8,708,029 common shares outstanding (post two consolidations: 1-for-15 in January 2025 and 1-for-10 in August 2025). Two warrant classes are outstanding: 5,366,726 BCTXL Warrants (issued January 15, 2026, exercise price $6.93, expiring January 2031) and 306,665 BCTXZ Warrants (issued April 28, 2025, exercise price $52.50, expiring April 2030). The company operates through four subsidiaries including Sapientia Pharmaceuticals Inc. No material financing, acquisition, or operational change is disclosed in this exhibit-focused filing.
Why this rating
Routine disclosure of registered securities structure and subsidiary list. No new financing, M&A, or business development. Standard periodic SEC filing compliance for a $37M company.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.